Top Banner
PRESCRIPTION DRUG MARKETS S. Vincent Rajkumar, M.D. Professor of Medicine Mayo Clinic
28

PRESCRIPTION DRUG MARKETS

Feb 22, 2022

Download

Documents

dariahiddleston
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: PRESCRIPTION DRUG MARKETS

PRESCRIPTION DRUG

MARKETS S. Vincent Rajkumar, M.D.

Professor of Medicine

Mayo Clinic

Page 2: PRESCRIPTION DRUG MARKETS

The High Cost of Cancer Drugs and What

We Can Do About It

Mustaqeem Siddiqui, MD

S. Vincent Rajkumar, MD

• 20 trials (8 RCTs)

• Regulatory trials

• Celgene (Thalidomide)

• Takeda (Ixazomib)

• Amgen (Carfilzomib)

• Janssen (Daratumurnab)

2012

Page 3: PRESCRIPTION DRUG MARKETS

Number of new myeloma

patients in the US in 2017: 30,000

Total lifetime costs to treat all patients

diagnosed in 2017: $22.4 billion

Excludes spending on hospital, infusion, laboratory, imaging, physician,

nursing and ancillary costs

Mailankody S. ASCO 2016 Source: Memorial Sloan Kettering Cancer Center

Page 4: PRESCRIPTION DRUG MARKETS

Drug Costs

Rajkumar SV. ASCO Ed Book. 2018

Page 5: PRESCRIPTION DRUG MARKETS

Drug Costs

Appx. Drug Cost Per Year* (U.S. Dollars)

Rajkumar SV. ASCO Ed Book. 2018

Page 6: PRESCRIPTION DRUG MARKETS
Page 7: PRESCRIPTION DRUG MARKETS
Page 8: PRESCRIPTION DRUG MARKETS

All new cancer drugs approved by FDA in 2017: >$100,000/year

Average = $150,000

Page 9: PRESCRIPTION DRUG MARKETS

$ 360 billion (USA)

(~10% healthcare spend)

Cancer Drugs

$50 billion (USA)

$60 billion (Rest of the world)

Page 10: PRESCRIPTION DRUG MARKETS
Page 11: PRESCRIPTION DRUG MARKETS

High Cost of Development

Cost-Benefit of New Drugs

Market Forces will Decide

Stifle Innovation

Asserted Reasons for High Costs

Page 12: PRESCRIPTION DRUG MARKETS

Fig 1. Cost trajectories of targeted therapies. Cumulative change (%) from baseline mean monthly cost by year. General inflation

rates are plotted as black dotted line; health-related inflation is plotted as red dotted line.

Published in: Noa Gordon; Salomon M. Stemmer; Dan Greenberg; Daniel A. Goldstein; JCO 2018, 36, 319-325. DOI:

10.1200/JCO.2016.72.2124.Copyright © 2017 American Society of Clinical Oncology.

Page 13: PRESCRIPTION DRUG MARKETS
Page 14: PRESCRIPTION DRUG MARKETS
Page 15: PRESCRIPTION DRUG MARKETS

30 million

diabetics in the

United States

1.3 million Type I

~30% of diabetics

take insulin

Source: CDC

Page 16: PRESCRIPTION DRUG MARKETS

Why are drug prices so high?

Page 17: PRESCRIPTION DRUG MARKETS

#1: Circumstances

Vulnerable populations willing to pay anything for

access to life-saving drugs

Page 18: PRESCRIPTION DRUG MARKETS

#2

Page 19: PRESCRIPTION DRUG MARKETS

#3: Patent Evergreening

• Discovered 1921

• 1923 First Insulin patented (Patent sold for $3)

• 1946 Improved NPH patented

• 1950s Improved Lente versions patented

• 1970s Improved pure insulins patented

• 1980s Recombinant human insulin patented

• 1990s Analog insulin patented

• 2000s Long acting analog insulin patented

Page 20: PRESCRIPTION DRUG MARKETS

#4: Planned Obsolescence

Greene JA, Riggs KR. N Engl J Med 2015;372:1171

Imatinib

Nilotinib

Page 21: PRESCRIPTION DRUG MARKETS

#5: Barriers to Generic and Biosimilar Entry

FDA obstacles

Lawsuits

Pay for delay

Page 22: PRESCRIPTION DRUG MARKETS

#6: Lock-step Pricing

Page 23: PRESCRIPTION DRUG MARKETS

#7: Middlemen

Business Insider

Page 24: PRESCRIPTION DRUG MARKETS

Why are drug prices so high?

3 reasons unique to the United States

1) Medicare cannot negotiate

2) Ban on personal importation

3) Reimbursement system encourages more expensive

options

Page 25: PRESCRIPTION DRUG MARKETS

Sanofi/Regeneron Amgen

Page 26: PRESCRIPTION DRUG MARKETS

Patients

Co-pay assistance

Pharma

$

Page 27: PRESCRIPTION DRUG MARKETS

The High Cost of Cancer Drugs and What

We Can Do About It

Mustaqeem Siddiqui, MD

S. Vincent Rajkumar, MD

• Nonprofit Generic and biosimilar manufacturers

2012

Page 28: PRESCRIPTION DRUG MARKETS

Questions?